The Transplant Company announced that it has submitted its comment letter in response to the draft Local Coverage Determination, LCD, related to molecular testing for solid organ transplant rejection.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDNA:
- Hold Rating for CareDx Amid Revenue Uncertainties and Valuation Discount
- CareDx initiated with a Market Perform at William Blair
- Cathie Wood Buys $172M Worth of Bullish Stock (BLSH) on Blockbuster IPO Debut, Trims Stake in SHOP
- CareDx price target lowered to $22 from $26 at BTIG
- CareDx Inc. Reports Strong Growth Amid Challenges